Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin versus metformin for insulin secretion and insulin resistance in adults with type 2 diabetes
jRCTs051220075Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Imeglimin group with Metformin group (2 arms). Primary endpoint: Change in HbA1c. Started Aug 2022; status: completed.
02
Drugs
imegliminmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220075.